Last 14.50 NOK
Change Today -0.10 / -0.68%
Volume 503.0
As of 7:05 AM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

nattopharma asa (NATTO) Snapshot

14.50 NOK
Previous Close
14.60 NOK
Day High
14.50 NOK
Day Low
14.50 NOK
52 Week High
05/13/13 - 26.70 NOK
52 Week Low
09/26/13 - 11.90 NOK
Market Cap
Average Volume 10 Days
0.03 NOK
Shares Outstanding
Dividend Yield
Current Stock Chart for NATTOPHARMA ASA (NATTO)

Related News

No related news articles were found.

nattopharma asa (NATTO) Related Businessweek News

No Related Businessweek News Found

nattopharma asa (NATTO) Details

NattoPharma ASA develops, distributes, and sells nutritional and pharmacy products, and provides associated services. The company offers MenaQ7 that provides vitamin K2 as a fermentation extract containing the menaquinone-7 for bone and cardiovascular health. It is also used as dietary supplements, as well as used in food supplements and fortified foods. The company has a research and development agreement with VitaK BV. NattoPharma ASA was founded in 2004 and is headquartered in Høvik, Norway.

Founded in 2004

nattopharma asa (NATTO) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 70.0K NOK
Chief Financial Officer
Total Annual Compensation: 768.0K NOK
Senior Vice President Sales & Marketing Europ...
Total Annual Compensation: 718.0K NOK
Marketing Manager
Total Annual Compensation: 388.0K NOK
Compensation as of Fiscal Year 2012.

nattopharma asa (NATTO) Key Developments

NattoPharma ASA to Report Q4, 2013 Results on Feb 17, 2014

NattoPharma ASA announced that they will report Q4, 2013 results on Feb 17, 2014

NattoPharma Announces the Introduction of MenaQ7 Crystals in Medical Food Called Fosteum PLUS

NattoPharma announced the introduction of MenaQ7 Crystals in a prescription medical food called Fosteum PLUS® from Primus Pharmaceuticals. This is the medical food product to incorporate vitamin K2, targeting bone health while protecting cardiovascular health. This represents an exclusive license for the bone-health category in medical foods.

NattoPharma ASA Announces New Study Shows MenaQ7 Vitamin K2 Plus Vitamin D Slows Progression of Arterial Calcification

NattoPharma ASA completed prospective randomized human clinical trail in patients with chronic renal disease, the cardiovascular effects of oral administration of vitamin K2 (MenaQ7® brand) plus vitamin D or vitamin D alone were evaluated. In this six-month study, the progression of coronary artery calcification index (CAC) and common carotid intima media thickness (CCA-IMT) - both markers of calcium deposits in arteries detected with computerized tomography -- showed a slower progression of the calcification in the vitamin K2/vitamin D group than detected in the vitamin D-alone group of patients.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NATTO:NO 14.50 NOK -0.10

NATTO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NATTO.
View Industry Companies

Industry Analysis


Industry Average

Valuation NATTO Industry Range
Price/Earnings 100.0x
Price/Sales 8.4x
Price/Book 3.4x
Price/Cash Flow 121.0x
TEV/Sales 7.5x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATTOPHARMA ASA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at